Download MendeleyStructure of SALO, a leishmaniasis vaccine candidate from the sand fly Lutzomyia longipalpis.
Asojo, O.A., Kelleher, A., Liu, Z., Pollet, J., Hudspeth, E.M., Rezende, W.C., Groen, M.J., Seid, C.A., Abdeladhim, M., Townsend, S., de Castro, W., Mendes-Sousa, A., Bartholomeu, D.C., Fujiwara, R.T., Bottazzi, M.E., Hotez, P.J., Zhan, B., Oliveira, F., Kamhawi, S., Valenzuela, J.G.(2017) PLoS Negl Trop Dis 11: e0005374-e0005374
- PubMed: 28278244
- DOI: https://doi.org/10.1371/journal.pntd.0005374
- Primary Citation of Related Structures:
5KX4 - PubMed Abstract:
Immunity to the sand fly salivary protein SALO (Salivary Anticomplement of Lutzomyia longipalpis) protected hamsters against Leishmania infantum and L. braziliensis infection and, more recently, a vaccine combination of a genetically modified Leishmania with SALO conferred strong protection against L. donovani infection. Because of the importance of SALO as a potential component of a leishmaniasis vaccine, a plan to produce this recombinant protein for future scale manufacturing as well as knowledge of its structural characteristics are needed to move SALO forward for the clinical path.
Organizational Affiliation:
Sabin Vaccine Institute and Texas Children's Hospital Center for Vaccine Development, National School of Tropical Medicine, Baylor College of Medicine, Houston, Texas, United States of America.
